Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call reveals strong financial performance, with significant revenue growth and a net profit turnaround due to strategic partnerships with AstraZeneca and Gilead. The cash runway supports ongoing projects, and milestone payments are lined up. Despite some uncertainties in timelines, the strategic partnerships and potential in the oncology field are promising. Analysts' questions highlight interest in future milestones and expansions, suggesting confidence in the company's direction. The positive financial results and strategic developments suggest a positive impact on stock price.

Key Financial Performance

Cash Balance As of December 31, 2025, the company had approximately $145.6 million in cash, cash equivalents, short-term bank deposits, and investments in marketable securities. This includes a $65 million upfront payment from AstraZeneca for monetizing a portion of future royalties.

Revenues For Q4 2025, revenues were approximately $67.3 million, and for the full year 2025, revenues were approximately $72.8 million. This is a significant increase compared to $1.5 million for Q4 2024 and $27.9 million for the full year 2024. The increase is attributed to the $65 million upfront payment from AstraZeneca and payments from the license agreement with Gilead.

R&D Expenses R&D expenses for Q4 2025 were approximately $5.5 million, and for the full year 2025, they were approximately $22.8 million. This is a decrease from $5.9 million for Q4 2024 and $24.8 million for the full year 2024. The decrease is due to lower clinical expenses from winding down prior trials, partially offset by increased expenses for the MAIA-ovarian trial initiated in 2025.

G&A Expenses G&A expenses for Q4 2025 were approximately $2.1 million, and for the full year 2025, they were approximately $8.9 million. This is slightly lower than $2.2 million for Q4 2024 and $9.4 million for the full year 2024.

Net Profit For Q4 2025, the company reported a net profit of approximately $56.8 million, or $0.60 per share, compared to a net loss of $6.1 million, or $0.07 per share, in Q4 2024. For the full year 2025, net profit was approximately $35.3 million, or $0.38 per share, compared to a net loss of $14.2 million, or $0.16 per share, in 2024. The improvement is due to increased revenues from the AstraZeneca and Gilead agreements.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

COM701: Advanced clinical programs, initiated new clinical trials, and expanded trial footprint globally in the U.S., Israel, and France. Presented clinical updates at ESMO conference. Demonstrated well-tolerated and durable responses in platinum-resistant ovarian cancer patients.

GS-0321: Initiated dosing in a Phase I dose escalation and expansion trial. Presented trial progress update at SITC. Licensed to Gilead with potential milestones up to $758 million and royalties.

Rilve (PD-1/TIGIT bispecific antibody): Monetized a portion of future royalties to AstraZeneca, receiving $65 million upfront and $25 million at the next milestone. Retained majority of royalty interest. AstraZeneca estimates peak annual revenue potential of over $5 billion.

Cash runway: Extended cash runway into 2029 through a nondilutive transaction with AstraZeneca. Current cash balance of $145.6 million as of December 31, 2025.

Leadership transition: CEO role transitioned to Eran Ophir in September 2025, with Anat becoming Executive Chair.

2026 strategic priorities: Focus on advancing COM701 in platinum-sensitive ovarian cancer and GS-0321 trials. Continued investment in early-stage pipeline leveraging AI-based discovery platform Unigen.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Cash runway dependency: The company’s cash runway is extended to 2029, but this is contingent on no further cash inflows. This dependency on a single financial assumption could pose risks if unexpected expenses arise or if anticipated milestones are delayed.

Clinical trial execution: The success of the COM701 and GS-0321 trials is critical to the company’s future. Any delays, failures, or adverse results in these trials could significantly impact the company’s strategic objectives and financial performance.

Regulatory approval risks: The company’s reliance on regulatory milestones, such as BLA acceptance for Rilve, introduces risks. Delays or failures in achieving these milestones could impact financial inflows and strategic plans.

Partnership dependency: The company is heavily reliant on partnerships with AstraZeneca and Gilead for milestone payments and royalties. Any changes in these partnerships or failures in their respective programs could adversely affect the company’s financials and operations.

Market competition: The immuno-oncology field is highly competitive. The success of Rilve and other assets depends on differentiation in drug format and clinical strategy, which may face challenges from competitors with similar or superior offerings.

Supply chain and operational risks: The expansion of clinical trial sites in multiple countries (U.S., Israel, France) introduces logistical and operational complexities that could lead to delays or increased costs.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Cash runway: The company expects its cash runway to fund operations into 2029, assuming no further cash inflows.

COM701 clinical trial: The MAIA-ovarian adaptive trial will continue execution in 2026, with an interim analysis expected in Q1 2027. This data could lead to a maintenance monotherapy path to registration and broader clinical development plans across ovarian cancer lines of treatment and other indications.

GS-0321 clinical trial: The ongoing Phase I trial for GS-0321, a potential first-in-class anti-IL-18 binding protein antibody, will continue in 2026. The trial includes dose escalation and dose expansion phases.

Rilve program by AstraZeneca: The company is closely tracking AstraZeneca's broad Phase III Rilve program, which includes 10 active trials. AstraZeneca estimates a non-risk-adjusted peak annual revenue potential of more than $5 billion for Rilve.

Early-stage pipeline: The company will focus on its early-stage pipeline in 2026, leveraging its AI-based computational engine, Unigen, to discover novel immuno-oncology assets.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:What can we expect in the 1Q '27 update with COM701, and what is the timeline and requirements for the path to registration?

A:The current trial is an adaptive trial design, and data maturation is anticipated in 1Q 2027. The timeline and requirements for registration depend on the totality of the data. Management is planning for success but is not ready to disclose subsequent plans or trials at this time. A positive monotherapy signal could open paths for combination strategies and other indications.

Q:What is the cadence of potential outlying milestones for rilvegostomig, and what is the next trigger for milestone payment?

A:The next milestone is BLA acceptance, which will entitle the company to an additional $25 million. In total, $195 million in milestones from AstraZeneca remain.

Q:Why has the interim analysis for the ovarian trial shifted from the second half of '26 to the first quarter of '27?

A:The shift was due to slower opening of major academic U.S. sites, which are now all open. AstraZeneca has also joined to contribute to the study. The trial is on track for a Q1 '27 readout, with events accumulating as expected.

Q:Are there discussions with AstraZeneca about expanding the use of COM902-derived TIGIT in additional multi-specific formats?

A:AstraZeneca controls rilvegostomig and is expanding its use, including a new Phase III trial in gastric cancer. COM902 is fully owned by the company and represents a separate opportunity for other collaborations.

Q:Where will the data for 0321 be presented, and will it include more than just initial safety?

A:The first patient was dosed in early '25. Data reporting will be aligned with Gilead and is expected to be presented at a scientific conference, typically including activity and safety. No specific commitments have been made yet.

Q:What might Compugen present at oncology meetings like ESMO and SITC through '26?

A:Currently disclosed plans include potential data presentations from Gilead and AstraZeneca programs, depending on their decisions. The MAIA study readout is expected next year.

Q:Review of Unclear Management Responses

A:Management avoided providing specific details on the timeline and requirements for COM701 registration, citing dependence on the totality of the data and ongoing discussions. They also did not commit to specific data presentation plans for 0321, deferring to alignment with Gilead.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

CGEN Transcript

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Positive3-2

Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript

Unknown11-10

The earnings call reveals significant challenges: declining revenues, a shift from profit to loss, and reliance on partnerships and milestone payments. Safety concerns with anti-TIGIT antibodies and competition in the market add risks. The Q&A section highlights uncertainties in trial timelines and outcomes, further dampening sentiment. Despite potential opportunities with COM902 and a cash runway until 2027, the overall financial and strategic outlook suggests a negative market reaction.

Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript

Unknown8-7

The earnings call presents several concerns: declining revenue and increased net loss, reliance on milestone payments, and negative market sentiment in the TIGIT space. The Q&A section highlighted management's reluctance to provide details, adding uncertainty. Despite a solid cash balance, the financial outlook is weak, with decreased revenue and increased competition in the ovarian cancer treatment market. These factors suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.

Compugen Ltd. (NASDAQ:CGEN) Q1 2025 Earnings Call Transcript

Unknown5-20

The earnings call presents a mixed picture. While there are positive developments, such as the partnership with AstraZeneca and a strong cash runway, there are also concerns like missed earnings expectations, leadership transition risks, and revenue decline. The Q&A section highlights management's cautious approach, particularly in providing specific details, which may not inspire strong investor confidence. Given the lack of clear catalysts for a significant price movement and the balanced pros and cons, a neutral sentiment is justified.

CGEN Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.